Drug Profile

OB 003

Alternative Names: OB-003

Latest Information Update: 01 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Orion Biotechnology Canada
Class Anti-inflammatories; Antineoplastics; Chemokines; Immunotherapies; Obesity therapies
Mechanism of Action CCR9 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Dec 2023 Discontinued - Preclinical for Cancer in Canada (unspecified route) (Orion Bioechnology pipeline, December 2023)
01 Dec 2023 Discontinued - Preclinical for Inflammatory bowel diseases in Canada (unspecified route) (Orion Bioechnology pipeline, December 2023)
14 May 2020 Preclinical trials in Cancer in Canada (unspecified route), prior to May 2020 (Orion Biotechnology Canada pipeline, May 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com